Megane Brusson

Paris, 75015, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Enhanced γ-globin reactivation and sickle cell correction through a repressor-to-activator motif switch in the HBG1/2 promoters.

Enhanced γ-globin reactivation and sickle cell correction through a repressor-to-activator motif switch in the HBG1/2 promoters.

Journal: Molecular therapy. Nucleic acids

Published: October 08, 2025

CleanFinder: a scalable framework for comprehensive genome editing analysis.

CleanFinder: a scalable framework for comprehensive genome editing analysis.

Journal: Trends in biotechnology

Published: September 08, 2025

A CRISPR/Cas approach to β-haemoglobinopathies

A CRISPR/Cas approach to β-haemoglobinopathies

Journal: Medecine sciences : M/S

Published: January 31, 2025

A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease.

A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease.

Journal: Blood

Published: January 03, 2025

Gene therapy for β-thalassemia: current and future options.

Gene therapy for β-thalassemia: current and future options.

Journal: Trends in molecular medicine

Published: October 08, 2024

Treating Sickle Cell Disease: Gene Therapy Approaches.

Treating Sickle Cell Disease: Gene Therapy Approaches.

Journal: Annual review of pharmacology and toxicology

Published: September 11, 2024

Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease.

Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease.

Journal: Nature communications

Published: August 14, 2024

Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses.

Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 26, 2024

An optimized SpCas9 high-fidelity variant for direct protein delivery.

An optimized SpCas9 high-fidelity variant for direct protein delivery.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 08, 2022

Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies.

Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies.

Journal: Molecular therapy. Nucleic acids

Published: July 30, 2022

CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy.

CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy.

Journal: Stem cells translational medicine

Published: April 29, 2022

Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression.

Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression.

Journal: Nature communications

Published: January 06, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026